Table 2.
Baseline characteristics and therapeutic intervention in 63 CD patients divided into group A (38 pts with active disease) and group B (25 pts with malabsorption due to intestinal resection).
| Group A Active Disease |
Group B Malabsorption |
|
|---|---|---|
| Patients (n) | 38 (19 M, 19 F) | 25 (15 F, 10 F) |
| BMI < 18.5 kg/m2 | 12/38 (31.6%) | 11/25 (44.0%) |
| WL ≥ 5–10% | 8/38 (21.1%) | 8/25 (32.0%) |
| Hb ≤ 10 g/dL | 9/38 (23.7%) | 6/25 (24.0%) |
| Lymph count < 1500/µL | 17/38 (44.7%) | 11/25 (44.0%) |
| Albumin < 3.5 g/dL | 17/38 (44.7%) | 8/25 (32.0%) |
| BChe < 5000 U/L | 12/38 (31.6%) | 12/25 (48.0%) |
|
Time from CD Diagnosis (months) |
median 5.8 (0.05–28.93) | median 10.6 (0.3–29.9) |
| Type of Surgical Intervention | ||
| No resections | 11 + 1 stricturoplastic | 1/25 (4.0%) |
| Ileo-colic resections | 15/38 (39.5%) | 8/25 (32.0%) |
| Multiple resection | 11/38 (28.9%) | 18/25 (72.0%) |
| Presence of a stoma | 4/38 (10.5%) | 9/25 (36.0%) |
| Jejuno/Ileostomy | 1/3 | 4/5 |
| Therapeutic Intervention | ||
| Dietetic indications | 38/38 (100%) | 25/25 (100%) |
| Oral supplements | 21/38 (55.3%) | 11/25 (44%) |
| Parenteral multivitamins and electrolytes |
9/38 (23.7%) | 0 |
| Parenteral iron | 0 | 9/25 (36.0%) |
| Peripheral parenteral nutrition | 3/38 (7.9%) | 3/25 (12.0%) |
| Central parenteral nutrition | 4/38 (10.5%) | 10/25 (4%) |
BMI: body mass index; BW loss (body weight loss in the last six months); Hb: Hemoglobin. Lymph count: lymphocyte count; BChe: butyryl-cholinesterase. WL: Weight Loss (body weight loss in the last six months); M: males; F: females, CD: Crohn’s Disease.